Qualigen Therapeutics (QLGN) - Wutah bathi ing taun lumaku

Lambang korporat lan logo Qualigen Corp (QLGN)

Qualigen Therapeutics (QLGN) demonstrates high macro-resilience, as the development of cancer and viral drugs remains independent of economic cycles. Growth is driven by the implementation of the FastPack system and the progress of the QN-302 drug. The year-over-year earnings per share trend shows that the value is fixed at 0.00. However, the company is currently experiencing a technological stalemate with a limited set of preclinical studies.

QLGN Wutah bathi saben saham ing taun lumaku Qualigen Therapeutics, Inc. (04.07.2022 - 19.11.2025)

Rincian metrik keuangan lan pasar qualigeninc.com (QLGN)

Analisis dhasar perusahaan:Qualigen, QLGN
Produk asil prodhuksi Qualigen Therapeutics

Analyzing net income per share dynamics is critical for selecting assets with a high margin of safety. This indicator captures the annual percentage change in EPS, reflecting real business efficiency and the impact of operating expenses on final profitability. In the case of Qualigen Therapeutics (QLGN), the annual EPS change range demonstrates how R&D outsourcing and reliance on external vendors affect the financial result.